Dr Reddy’s Strikes $50m Deal For Eton Injectables
Acquisition Of Branded And Generic Hospital Drugs Offers ‘Foundational Footprint’
Executive Summary
Dr Reddy’s says it has gained a “foundational footprint” that will help improve access to critical care products for hospitals and health systems in the US, after striking a deal worth up to $50m to acquire a portfolio of branded and generic injectables from Eton Pharmaceuticals.
You may also be interested in...
Study Offers Support For Biosimilar-To-Biosimilar Switching
A new paper has examined the issue of biosimilar-to-biosimilar switching, concluding that it is a safe and effective clinical practice but highlighting a lack of current health authority regulations or guidance on the subject.
Entry Deadline Looms For GGB Awards
There is now just one week to go until the 19 August deadline for companies to submit entries for the Global Generics & Biosimilars Awards 2022, which returns to Frankfurt this November.
Study Offers Support For Biosimilar-To-Biosimilar Switching
A new paper has examined the issue of biosimilar-to-biosimilar switching, concluding that it is a safe and effective clinical practice but highlighting a lack of current health authority regulations or guidance on the subject.